Title
Author
DOI
Article Type
Special Issue
Volume
Issue
A ten-year remission maintained by 6272 mg (3920 mg/m2) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer
1Sisters of Charity Hospital, Buffalo NY, USA
*Corresponding Author(s): M. Steven Piver E-mail:
Since cisplatin is a heavy metal, renal and neurotoxicity is considered to be dose limiting in solid tumors. The current case is unusual in that remission has been maintained in a patient with recurrent epithelial ovarian cancer by cisplatin-based chemotherapy without evidence of renal or neurotoxicity, while receiving a total dose of 6,270 mg (3,920 mg/m2) of cisplatin over 11 1/2 years.
Chemotherapy; Cisplatin; Ovarian cancer
M. Steven Piver. A ten-year remission maintained by 6272 mg (3920 mg/m2) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer . European Journal of Gynaecological Oncology. 2001. 22(6);403-405.
[1] PiverM . S., Lele S. B.,P atsner B.M, cPheeM . E.; "1.5 - 5 years of uninterrupted cis-diamminedichloroplatinum II chemotherapy for metastatic cervical cancer". Gynecol. Oneal., 1987, 27, 24.
[2] Sutton G. P., Tehman F. B., Einhorn L. H. et al.: "Ten year followup of patients receiving cisplatin, doxarubicin, and cyclophospha-mide chemotherapy for advanced epithelial ovarian cancer". J. Clin. Oncol., 1989, 7, 223.
[3] Eltabbakh D. H., Hempling R., PiverM . S., Recio F. O., Blumenson L. E.: "Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer". Gyn. Oneal., 1998, 71,190.
[4] PiverM . S., Lele S. B., Marchetti D. L. et al.:'The impact of aggessive debulking surgery and cisplatin-based chemotherapy on progression free survival in stage III and IV ovarian carcinoma". J. Clin. Oneal., 1988, 6, 983.
[5] Baker T. R., PiverM . S., Hempling R. E.:'The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma". Eur. J. Gynecol. Oncol., 1993, 14, 18.
[6] Goldberg J.M., Piver M. S., Hempling R. E., Recio F. O.: "Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer". Gynecol. Oneal., 1996, 63, 312.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top